Effects of traditional Chinese medicine Chaihu-Shugan-San aqueous extract on high-fat diet-induced liver steatosis in rats via intestinal microbiota metabolite SCFAs and its receptor Gpr43/109a

Abstract

Non-alcoholic fatty liver disease (NAFLD) is one of the most common chronic liver diseases in adults around China and the world. The study explores protective effect of traditional Chinese medicine Chaihu-Shugan-San decoction on high-fat diet-induced liver steatosis in rats via intestinal microbiota metabolite short-chain fatty acids (SCFAs) and its receptor Gpr43/109a. Fifteen male Sprague–Dawley rats were randomly divided into three groups of five rats each: the control group (standard diet), High-fat diet (HFD)-induced NAFLD group (83% standard diet + 10% lard oil + 5% sucrose + 1.5% cholesterol + 0.5% cholate), and Chaihu-Shugan-San (CSS)-treated group (HFD + 9.6 g/kg body weight gastric administration of CSS decoction every day). Body composition, hepatic fat, intestinal mucosal permeability and SCFAs, Gpr43 and Gpr109a expression in colonic tissues were assessed. Compared with NAFLD group, CSS decoction significantly reduced body weight, liver weight, hepatic triglyceride and total cholesterol (P < 0.05), and increased colonic SCFAs and occludin expression. The levels of Gpr43 and Gpr109a also changed significantly (P < 0.05). Protective effect of CSS decoction in HFD-induced NAFLD rats might improve intestinal mucosal permeability and intestinal microbiota metabolite SCFAs through Gpr43 and Gpr109a pathways in colonic tissues.

This is a preview of subscription content, access via your institution.

We’re sorry, something doesn't seem to be working properly.

Please try refreshing the page. If that doesn't work, please contact support so we can address the problem.

Fig.1
Fig.2
Fig.3

References

  1. Byrne CD, Targher G (2015) NAFLD: A multisystem disease. J Hepatol 62(1S):S47–S64

    Article  Google Scholar 

  2. Cao W, Zhang W, Liu J et al (2011) Paeoniflorin improves survival in LPS-challenged mice through the suppression of TNF-alpha and IL-1beta release and augmentation of IL-10 production. Int Immunopharmacol 11(2):172–178

    CAS  Article  Google Scholar 

  3. Cornall LM, Mathai ML, Hryciw DH, McAinch AJ (2011) Diet-induced obesity up-regulates the abundance of GPR43 and GPR120 in a tissue specific manner. Cell Physiol Biochem Int J Exp Cell Physiol, Biochem Pharm 28:949–958

    CAS  Article  Google Scholar 

  4. De VF, Kovatcheva-Datchary P, Goncalves D et al (2014) Microbiota-generated metabolites promote metabolic benefits via gut-brain neural circuits. Cell 156:84–96

    Article  Google Scholar 

  5. Donnelly KL, Smith CI, Schwarzenberg SJ et al (2005) Sources of fatty acids stored in liver and secreted via lipoproteins in patients with nonalcoholic fatty liver disease. J Clin Invest 115(5):1343–1351

    CAS  Article  Google Scholar 

  6. Giorgio V, Miele L, Principessa L et al (2014a) Intestinal permeability is increased in children with non-alcoholic fatty liver disease, and correlates with liver disease severity. Dig Liver Dis 46:556–560

    Article  Google Scholar 

  7. Giorgio V, Miele L, Principessa L et al (2014b) Intestinal permeability is increased in children with non-alcoholic fatty liver disease, and correlates with liver disease severity. Digest Liver Dis 46(6):556–560

    Article  Google Scholar 

  8. Gong XW, Yang QH, Yan HZ et al (2014) Effects of soothing liver and invigorating spleen recipes on LPS-induced hepatocytes injury of rats and TLR4/p38MAPK signal pathway. China J Chin Mater Med 39:4027–4033

    Google Scholar 

  9. Hollander D (1988) Crohn’s disease–a permeability disorder of the tight junction? Gut 29(12):1621–1624

    CAS  Article  Google Scholar 

  10. Hu ED, Chen DZ, Wu JL et al (2018) High fiber dietary and sodium butyrate attenuate experimental autoimmune hepatitis through regulation of immune regulatory cells and intestinal barrier. Cell Immunol 328:24–32

    CAS  Article  Google Scholar 

  11. Hudson BD, Due-Hansen ME, Christiansen E et al (2013) Defining the molecular basis for the first potent and selective orthosteric agonists of the FFA2 free fatty acid receptor. J Biol Chem 288:17296–17312

    CAS  Article  Google Scholar 

  12. Liang Y, Zhang Y, Deng Y et al (2018) Chaihu-Shugan-San decoction modulates intestinal microbe dysbiosis and alleviates chronic metabolic inflammation in NAFLD Rats via the NLRP3 inflammasome pathway. Evid Based Complement Altern Med 2018:9390786

    Google Scholar 

  13. Liang Y, Lin C, Huang S, Xu Y. Traditional Chinese Medicine and Intestinal Microbiota: A Complementary and Integrative Health Approach to Ameliorate Obesity-related Diseases. Holistic Nursing Practice, 2019.1.10. [Epub ahead of print]

  14. Lu CN, Yuan ZG, Zhang XL et al (2012) Saikosaponin a and its epimer saikosaponin d exhibit anti-inflammatory activity by suppressing activation of NF-kappaB signaling pathway. Int Immunopharmacol 14(1):121–126

    CAS  Article  Google Scholar 

  15. Lu Y, Fan C, Li P, Lu Y, Chang X, Qi K (2016) Short chain fatty acids prevent high-fat-diet-induced obesity in mice by regulating g protein-coupled receptors and gut microbiota. Sci Rep 6:37589

    CAS  Article  Google Scholar 

  16. Ma Z, Chu L, Liu H et al (2016) Paeoniflorin alleviates non-alcoholic steatohepatitis in rats: Involvement with the ROCK/NF-kappaB pathway. Int Immunopharmacol 38:377–384

    CAS  Article  Google Scholar 

  17. Macia L, Tan J, Vieira AT et al (2015) Metabolite-sensing receptors GPR43 and GPR109A facilitate dietary fibre-induced gut homeostasis through regulation of the inflammasome. Nat Commun 6:6734

    CAS  Article  Google Scholar 

  18. Mahmoud AM (2014) Hesperidin protects against cyclophosphamide-induced hepatotoxicity by upregulation of PPARgamma and abrogation of oxidative stress and inflammation. Can J Physiol Pharmacol 92(9):717–724

    CAS  Article  Google Scholar 

  19. Miele L, Valenza V, la Torre G et al (2009) Increased intestinal permeability and tight junction alterations in nonalcoholic fatty liver disease. Hepatology 49(6):1877–1887

    CAS  Article  Google Scholar 

  20. Naowaboot J, Piyabhan P, Munkong N et al (2016) Ferulic acid improves lipid and glucose homeostasis in high-fat diet-induced obese mice. Clin Exp Pharmacol Physiol 43(2):242–250

    CAS  Article  Google Scholar 

  21. Pan C, Huang JR (2009) Clinical observation on the treatment of 82 cases of non-alcoholic fatty liver disease. Lishizhen Med Mater Med Res 20(8):2010–2011

    Google Scholar 

  22. Rotimi SO, Bankole GE, Adelani IB et al (2016) Hesperidin prevents lipopolysaccharide-induced endotoxicity in rats. Immunopharmacol Immunotoxicol 38(5):364–371

    CAS  Article  Google Scholar 

  23. Schaefer K (1995) Analysis of short chain fatty acids from different intestinal samples by capillary gas chromatography. Chromatographia 40:550–556

    CAS  Article  Google Scholar 

  24. Singh N, Gurav A, Sivaprakasam S, Brady E, Padia R, Shi H, Thangaraju M, Prasad PD, Manicassamy S, Munn DH, Lee JR, Offermanns S, Ganapathy V (2014a) Activation of Gpr109a, receptor for niacin and the commensal metabolite butyrate, suppresses colonic inflammation and carcinogenesis. Immunity 40(1):128–139

    CAS  Article  Google Scholar 

  25. Singh N, Gurav A, Sivaprakasam S et al (2014b) Activation of Gpr109a, receptor for niacin and the commensal metabolite butyrate, suppresses colonic inflammation and carcinogenesis. Immunity 40:128–139

    CAS  Article  Google Scholar 

  26. Wei Z, Wang J, Shi M et al (2016) Saikosaponin a inhibits LPS-induced inflammatory response by inducing liver X receptor alpha activation in primary mouse macrophages. Oncotarget 7(31):48995–49007

    Article  Google Scholar 

  27. Willemsen LE, Koetsier MA, van Deventer SJ, van Tol EA (2003) Short chain fatty acids stimulate epithelial mucin 2 expression through differential effects on prostaglandin E(1) and E(2) production by intestinal myofibroblasts. Gut 52:1442–1447

    CAS  Article  Google Scholar 

  28. Younossi ZM, Koenig AB, Abdelatif D et al (2016) Global epidemiology of nonalcoholic fatty liver disease-Meta-analytic assessment of prevalence, incidence, and outcomes. Hepatology 64:73–84

    Article  Google Scholar 

  29. Zhang LD, Sun XH, Wei W, Yao WW (2014) Systematic evaluation and meta analysis on nonalcoholic fatty liver disease treated with Chaihu Shugan San. World J Integr Tradit West Med 9:1004–1007

    Google Scholar 

  30. Zhang L, Yang B, Yu B (2015) Paeoniflorin protects against nonalcoholic fatty liver disease induced by a high-fat diet in mice. Biol Pharm Bull 38(7):1005–1011

    CAS  Article  Google Scholar 

Download references

Acknowledgements

This work was supported in part by National Health and Family Planning Commission of Guangdong in China (no. A2017228, A2017140, A2020137 and A2021000), Traditional Chinese Medicine Bureau of Guangdong in China (no. 20161065 and 20201075), Natural Science Foundation of Guangdong in China (no. 2016A030313824 and 2019A1515010865) and National Natural Science Foundation of China (no. 81774165 and 81873206).

Author information

Affiliations

Authors

Corresponding author

Correspondence to Qinhe Yang.

Ethics declarations

Ethical statement

The study received clearance from the Laboratory Animal Ethics Committee Jinan University (Reference no. 20151222175501, Guangzhou, China).

Conflict of interest

All authors declared no potential conflicts of interest.

Additional information

Publisher's Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Rights and permissions

Reprints and Permissions

About this article

Verify currency and authenticity via CrossMark

Cite this article

Liang, Y., Lin, C., Deng, Y. et al. Effects of traditional Chinese medicine Chaihu-Shugan-San aqueous extract on high-fat diet-induced liver steatosis in rats via intestinal microbiota metabolite SCFAs and its receptor Gpr43/109a. ADV TRADIT MED (ADTM) (2021). https://doi.org/10.1007/s13596-021-00552-z

Download citation

Keywords

  • Traditional chinese medicine
  • Chaihu-shugan-san
  • Non-alcoholic fatty liver disease
  • Scfas